3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods

References

• I. Mata, J. Kachergus, J. Taylor, S. Lincoln, J. Aasly, T. Lynch, M. Hulihan, S. Cobb, R.-M. Wu, C.-S. Lu, C. Lahoz, Z. Wszolek, and M. Farrer, Lrrk2 pathogenic substitutions in Parkinson's disease, Neurogenetics 6 (2005), pp. 171–177.
   PubMed Web of Science ®Google Scholar
• A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R.J. Uitti, D.B. Calne, A.J. Stoessl, R.F. Pfeiffer, N. Patenge, I.C. Carbajal, P. Vieregge, F. Asmus, B. Müller-Myhsok, D.W. Dickson, T. Meitinger, T.M. Strom, Z.K. Wszolek, and T. Gasser, Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology, Neuroon 44 (2004), pp. 601–607.
   PubMed Web of Science ®Google Scholar
• J. Simón-Sánchez, V. Herranz-Pérez, F. Olucha-Bordonau, and J. Pérez-Tur, LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain, Eur. J. Neurosci. 23 (2006), pp. 659–666.
   PubMed Web of Science ®Google Scholar
• C. Paisán-Ruíz, S. Jain, E.W. Evans, W.P. Gilks, J. Simón, M. van der Brug, A.L. de Munain, and S. Aparicio, A.M.n. Gil, N. Khan, J. Johnson, J.R. Martinez, D. Nicholl, I.M. Carrera, A.S. PeHa, R. de Silva, A. Lees, J.F. Martí-Massó, J. Pérez-Tur, N.W. Wood, and A.B. Singleton, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, Neuron 44 (2004), pp. 595–600.
   PubMed Web of Science ®Google Scholar
• C. Paisán-Ruíz, P. Nath, N. Washecka, J.R. Gibbs, and A.B. Singleton, Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls, Hum. Mutat. 29 (2008), pp. 485–490.
   PubMed Web of Science ®Google Scholar
• M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E.S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W.G. Johnson, A.M. Lazzarini, R.C. Duvoisin, G. Di Iorio, L.I. Golbe, and R.L. Nussbaum, Mutation in the α-synuclein gene identified in families with Parkinson's disease, Science 276 (1997), pp. 2045–2047.
   PubMed Web of Science ®Google Scholar
• O.A. Ross, M. Toft, A.J. Whittle, J.L. Johnson, S. Papapetropoulos, D.C. Mash, I. Litvan, M.F. Gordon, Z.K. Wszolek, M.J. Farrer, and D.W. Dickson, Lrrk2 and Lewy body disease, Annals Neurol. 59 (2006), pp. 388–393.
   PubMed Web of Science ®Google Scholar
• H. Chen, B.K. Chan, J. Drummond, A.A. Estrada, J. Gunzner-Toste, X. Liu, Y. Liu, J. Moffat, D. Shore, Z.K. Sweeney, T. Tran, S. Wang, G. Zhao, H. Zhu, and D.J. Burdick, Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling, J. Med. Chem. 55 (2012), pp. 5536–5545.
   PubMed Web of Science ®Google Scholar
• L. Wang, C. Xie, E. Greggio, L. Parisiadou, H. Shim, L. Sun, J. Chandran, X. Lin, C. Lai, W.-J. Yang, D.J. Moore, T.M. Dawson, V.L. Dawson, G. Chiosis, M.R. Cookson, and H. Cai, The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2, J. Neurosci. 28 (2008), pp. 3384–3391.
   PubMed Web of Science ®Google Scholar
• A.W. Garofalo, M. Adler, D.L. Aubele, S. Bowers, M. Franzini, E. Goldbach, C. Lorentzen, R.J. Neitz, G.D. Probst, K.P. Quinn, P. Santiago, H.L. Sham, D. Tam, A.P. Truong, X.M. Ye, and Z. Ren, Novel cinnoline-based inhibitors of LRRK2 kinase activity, Bioorg. Med. Chem. Lett. 23 (2013), pp. 71–74.
   PubMed Web of Science ®Google Scholar
• A.W. Garofalo, M. Adler, D.L. Aubele, E.F. Brigham, D. Chian, M. Franzini, E. Goldbach, G.T. Kwong, R. Motter, G.D. Probst, K.P. Quinn, L. Ruslim, H.L. Sham, D. Tam, P. Tanaka, A.P. Truong, X.M. Ye, and Z. Ren, Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors, Bioorg. Med. Chem. Lett. 23 (2013), pp. 1974–1977.
   PubMed Web of Science ®Google Scholar
• M. Liu, S. Poulose, E. Schuman, A.D. Zaitsev, B. Dobson, K. Auerbach, K. Seyb, G.D. Cuny, M.A. Glicksman, R.L. Stein, and Z. Yue, Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2-Discovery of LRRK2 inhibitors, Anal. Biochem. 404 (2010), pp. 186–192.
   PubMed Web of Science ®Google Scholar
• A.D. Reith, P. Bamborough, K. Jandu, D. Andreotti, L. Mensah, P. Dossang, H.G. Choi, X. Deng, J. Zhang, D.R. Alessi, and N.S. Gray, GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor, Bioorg. Med. Chem. Lett. 22 (2012), pp. 5625–5629.
   PubMed Web of Science ®Google Scholar
• T. Troxler, P. Greenidge, K. Zimmermann, S. Desrayaud, P. Drückes, T. Schweizer, D. Stauffer, G. Rovelli, and D.R. Shimshek, Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2, Bioorg. Med. Chem. Lett. 23 (2013), pp. 4085–4090.
   PubMed Web of Science ®Google Scholar
• J. Zhang, X. Deng, H.G. Choi, D.R. Alessi, and N.S. Gray, Characterization of TAE684 as a potent LRRK2 kinase inhibitor, Bioorg. Med. Chem. Lett. 22 (2012), pp. 1864–1869.
   PubMed Web of Science ®Google Scholar
• W.W. Smith, Z. Pei, H. Jiang, D.J. Moore, Y. Liang, A.B. West, V.L. Dawson, T.M. Dawson, and C.A. Ross, Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration, Proc. Nat.l Acad. Sci. U.S.A. 102 (2005), pp. 18676–18681.
   PubMed Web of Science ®Google Scholar
• M. Franzini, X.M. Ye, M. Adler, D.L. Aubele, A.W. Garofalo, S. Gauby, E. Goldbach, G.D. Probst, K.P. Quinn, P. Santiago, H.L. Sham, D. Tam, A. Truong, and Z. Ren, Triazolopyridazine LRRK2 kinase inhibitors, Bioorg. Med. Chem. Lett. 23 (2013), pp. 1967–1973.
   PubMed Web of Science ®Google Scholar
• E. Pourbasheer, R. Aalizadeh, M.R. Ganjali, P. Norouzi, J. Shadmanesh, and C. Methenitis, QSAR study of Nav1.7 antagonists by multiple linear regression method based on genetic algorithm (GA-MLR), Med. Chem. Res. 23 (2014), pp. 2264–2276.
   Web of Science ®Google Scholar
• E. Pourbasheer, R. Aalizadeh, M.R. Ganjali, P. Norouzi, and A. Banaei, QSAR study of mGlu5 inhibitors by genetic algorithm-multiple linear regressions, Med. Chem. Res. 23 (2014), pp. 3082–3091.
   Web of Science ®Google Scholar
• E. Pourbasheer, R. Aalizadeh, M.R. Ganjali, and P. Norouzi, QSAR study of IKKβ inhibitors by the genetic algorithm: Multiple linear regressions, Med. Chem. Res. 23 (2014), pp. 57–66.
   Web of Science ®Google Scholar
• E. Pourbasheer, R. Aalizadeh, M.R. Ganjali, and P. Norouzi, QSAR study of α1β4 integrin inhibitors by GA-MLR and GA-SVM methods, Struct. Chem. 25 (2014), pp. 355–370.
   Web of Science ®Google Scholar
• E. Pourbasheer, A. Beheshti, H. Khajehsharifi, M.R. Ganjali, and P. Norouzi, QSAR study on hERG inhibitory effect of kappa opioid receptor antagonists by linear and non-linear methods, Med. Chem. Res. 22 (2013), pp. 4047–4058.
   Web of Science ®Google Scholar
• L. Firoozpour, K. Sadatnezhad, S. Dehghani, E. Pourbasheer, A. Foroumadi, A. Shafiee, and M. Amanlou, An efficient piecewise linear model for predicting activity of caspase-3 inhibitors, DARU, J. Pharm. Sci. 20 (2012), pp. 1–6.
   Google Scholar
• S. Yousefinejad, and B. Hemmateenejad, Chemometrics tools in QSAR/QSPR studies: A historical perspective, Chemometr. Intell. Lab. Sys. 149 (2015), pp. 177–204.
   Web of Science ®Google Scholar
• E. Pourbasheer, and S. Shokouhi, Tabar, V.H. Masand, R. Aalizadeh, and M.R. Ganjali, 3D-QSAR and docking studies on adenosine A2A receptor antagonists by the CoMFA method, SAR QSAR Environ. Res. 26 (2015), pp. 461–477.
   PubMed Web of Science ®Google Scholar
• E. Pourbasheer, R. Bazl, and M. Amanlou, Molecular docking and 3D-QSAR studies on the MAPKAP-K2 inhibitors, Med. Chem. Res. 23 (2014), pp. 2252–2263.
   Web of Science ®Google Scholar
• E. Pourbasheer and M. Amanlou, 3D-QSAR analysis of anti-cancer agents by CoMFA and CoMSIA, Med. Chem. Res. 23 (2014), pp. 800–809.
   Web of Science ®Google Scholar
• E. Pourbasheer, R. Aalizadeh, S. Shokouhi Tabar, M.R. Ganjali, P. Norouzi, and J. Shadmanesh, 2D and 3D-QSAR study of Hepatitis C Virus NS5B polymerase inhibitors by CoMFA and CoMSIA methods, J. Chem. Inf. Model. 54 (2014), pp. 2902–2914.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988), pp. 5959–5967.
   PubMed Web of Science ®Google Scholar
• G. Klebe, U. Abraham, and T. Mietzner, Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 37 (1994), pp. 4130–4146.
   PubMed Web of Science ®Google Scholar
• P. Galatsis, J.L. Henderson, B.L. Kormos, S. Han, R.G. Kurumbail, T.T. Wager, P.R. Verhoest, G.S. Noell, Y. Chen, E. Needle, Z. Berger, S.J. Steyn, C. Houle, and W.D. Hirst, Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold, Bioorg Med Chem Lett. 24 (2014), pp. 4132–4140.
   PubMed Web of Science ®Google Scholar
• A.K. Jain, Data clustering: 50 years beyond K-means, Pattern Recogn. Lett. 31 (2010), pp. 651–666.
   Web of Science ®Google Scholar
• J.A. Hartigan, Clustering Algorithms, John Wiley & Sons, Inc., 1975.
   Google Scholar
• A.K. Jain, M.N. Murty, and P.J. Flynn, Data clustering: A review, ACM Comput. Surv. 31 (1999), pp. 264–323.
   Web of Science ®Google Scholar
• H.T. Manual, SYBYL 7.3, Tripos International, St. Louis, Missouri, USA, 2006.
   Google Scholar
• J. Gasteiger, and M. Marsili, Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges, Tetrahedron 36 (1980), pp. 3219–3228.
   Web of Science ®Google Scholar
• M. Clark, R.D. Cramer, and N. Van Opdenbosch, Validation of the general purpose tripos 5.2 force field, J. Comput. Chem. 10 (1989), pp. 982–1012.
   Web of Science ®Google Scholar
• R. Aalizadeh, E. Pourbasheer, and M.R. Ganjali, Analysis of B-RafV600E inhibitors using 2D and 3D-QSAR, molecular docking and pharmacophore studies, Mol. Divers. 19 (2015), pp. 915–930.
   PubMed Web of Science ®Google Scholar
• E. Pourbasheer, R. Aalizadeh, H.M. Shiri, A. Banaei, and M.R. Ganjali, 2D and 3D-QSAR analysis of pyrazole-thiazolinone derivatives as EGFR kinase inhibitors by CoMFA and CoMSIA, Curr. Comput. Aided Drug Des. 11 (2016), pp. 292–303.
   Web of Science ®Google Scholar
• G. Folkers, A. Merz, and D. Rognan, Theory methods and applications, in 3D-QSAR in Drug Design, H. Kubinyi, ed., ESCOM, Leiden, the Netherlands, 1994, pp. 583–618.
   Google Scholar
• V.N. Viswanadhan, A.K. Ghose, G.R. Revankar, and R.K. Robins, Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics, J. Chem. Inf. Comput. Sci. 29 (1989), pp. 163–172.
   Google Scholar
• S. Wold, A. Ruhe, H. Wold, and I. Dunn, The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses, SIAM J. Sci. Comput. 5 (1984), pp. 735–743.
   Web of Science ®Google Scholar
• B. Bush, and R. Nachbar Jr, Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA, J. Computer-Aided Mol. Des. 7 (1993), pp. 587–619.
   PubMed Web of Science ®Google Scholar
• Y.C. Martin, and P. Willett, Designing Bioactive Molecules: Three-Dimensional Techniques and Applications, American Chemical Society, Washington DC, 1998.
   Google Scholar
• R. Wehrens, H. Putter, and L.M.C. Buydens, The bootstrap: A tutorial, Chemometr. Intell. Lab. Syst. 54 (2000), pp. 35–52.
   Web of Science ®Google Scholar
• K. Roy, P. Chakraborty, I. Mitra, P.K. Ojha, S. Kar, and R.N. Das, Some case studies on application of “rm2” metrics for judging quality of quantitative structure–activity relationship predictions: Emphasis on scaling of response data, J. Comput. Chem. 34 (2013), pp. 1071–1082.
   PubMed Web of Science ®Google Scholar
• A. Golbraikh, and A. Tropsha, Beware of q2!, J. Mol. Graph. Model. 20 (2002), pp. 269–276.
   PubMed Web of Science ®Google Scholar
• N. Chirico, and P. Gramatica, Real external predictivity of QSAR models: How to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient, J. Chem. Inf. Model. 51 (2011), pp. 2320–2335.
   PubMed Web of Science ®Google Scholar
• N. Chirico, and P. Gramatica, Real external predictivity of QSAR models. Part 2. New intercomparable thresholds for different validation criteria and the need for scatter plot inspection, J. Chem. Inf. Model. 52 (2012), pp. 2044–2058.
   PubMed Web of Science ®Google Scholar
• L.I. Lin, A concordance correlation coefficient to evaluate reproducibility, Biometrics 45 (1989), pp. 255–268.
   PubMed Web of Science ®Google Scholar
• G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem. 30 (2009), pp. 2785–2791.
   PubMed Web of Science ®Google Scholar
• U.C. Singh, and P.A. Kollman, An approach to computing electrostatic charges for molecules, J. Comput. Chem. 5 (1984), pp. 129–145.
   Web of Science ®Google Scholar
• G. Wolber and T. Langer, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model. 45 (2004), pp. 160–169.
   Web of Science ®Google Scholar
• L.M. Shi, H. Fang, W. Tong, J. Wu, R. Perkins, R.M. Blair, W.S. Branham, S.L. Dial, C.L. Moland, and D.M. Sheehan, QSAR models using a large diverse set of estrogens, J. Chem. Inf. Comput. Sci. 41 (2000), pp. 186–195.
   Google Scholar
• V. Consonni, D. Ballabio, and R. Todeschini, Comments on the definition of the Q2 parameter for QSAR validation, J. Chem. Inf. Model. 49 (2009), pp. 1669–1678.
   PubMed Web of Science ®Google Scholar
• K.P. Singh, and S. Gupta, Nano-QSAR modeling for predicting biological activity of diverse nanomaterials, RSC Adv. 4 (2014), pp. 13215–13230.
   Web of Science ®Google Scholar